Skip to main content

COVID-19 Topic Center

Comparative Effectiveness News

Conference Insider
Researchers presented data comparing total healthcare cost in pre- and post-stroke periods between rivaroxaban- and warfarin-treated non-valvular atrial fibrillation NVAF patients.at the International Stroke Conference 2020. The researchers study results showed substantial increase in total cost…
Conference Insider
Findings being presented at the 2019 ASH Annual Meeting demonstrate that vosaroxin and infusional cytarabine is a safe treatment regimen for newly diagnosed patients with acute myeloid leukemia (AML). “Until recently, the anthracycline and cytarabine based induction remained unchanged for over 4…
News
Idelalisib is safe and improves survival rates among patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with rituximab monotherapy, according to long-term efficacy and safety results from a phase 3 extension study (J Clin Oncol. 2019 Apr 17. Epub ahead of print). “A…
Conference Insider
According to a presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer…
Conference Insider
Research presented at the AMCP 2018 Annual Meeting found that Shingrix (non-live adjuvanted subunit vaccine; GlaxosmithKline) is cost-effective when compared with no vaccination and cost-saving compared with an older shingles vaccine. In their presentation, Brandon J Patterson, PhD, PharmD, of US…
Conference Insider
Recent research presented at the ACC 2018 Scientific Session found that urgent or emergent transcatheter aortic valve replacement (TAVR) has acceptable outcomes when compared with elective TAVR.  “This study reports that despite patients undergoing urgent/emergent TAVR having higher burden of…
Back to Top